Utah Medical Products (NASDAQ:UTMD) Stock Crosses Above 200-Day Moving Average – Should You Sell?

Shares of Utah Medical Products, Inc. (NASDAQ:UTMD) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $59.23 and traded as high as $64.24. Utah Medical Products shares last traded at $63.73, with a volume of 12,256 shares traded.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of Utah Medical Products in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Utah Medical Products presently has a consensus rating of “Sell”.

Utah Medical Products Price Performance

The stock’s 50 day simple moving average is $59.29 and its two-hundred day simple moving average is $59.23. The firm has a market cap of $203.94 million, a P/E ratio of 18.31 and a beta of 0.34.

Utah Medical Products (NASDAQ:UTMD) last posted its quarterly earnings results on Thursday, January 29th. The medical instruments supplier reported $0.80 earnings per share for the quarter. The company had revenue of $9.04 million for the quarter. Utah Medical Products had a return on equity of 9.60% and a net margin of 29.30%.

Utah Medical Products Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 3rd. Stockholders of record on Tuesday, March 17th will be given a $0.31 dividend. This represents a $1.24 annualized dividend and a dividend yield of 1.9%. The ex-dividend date of this dividend is Tuesday, March 17th. Utah Medical Products’s payout ratio is currently 35.63%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of UTMD. First Horizon Advisors Inc. grew its holdings in shares of Utah Medical Products by 159.7% during the second quarter. First Horizon Advisors Inc. now owns 587 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 361 shares during the last quarter. Comerica Bank lifted its position in Utah Medical Products by 435.6% in the 3rd quarter. Comerica Bank now owns 541 shares of the medical instruments supplier’s stock valued at $34,000 after acquiring an additional 440 shares in the last quarter. CWM LLC boosted its stake in Utah Medical Products by 287.4% during the 2nd quarter. CWM LLC now owns 829 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 615 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Utah Medical Products by 89.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,060 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 501 shares in the last quarter. Finally, Cornerstone Planning Group LLC raised its stake in shares of Utah Medical Products by 3,272.5% in the third quarter. Cornerstone Planning Group LLC now owns 1,349 shares of the medical instruments supplier’s stock worth $85,000 after purchasing an additional 1,309 shares during the last quarter. 69.60% of the stock is owned by hedge funds and other institutional investors.

About Utah Medical Products

Utah Medical Products, Inc (NASDAQ: UTMD), headquartered in Midvale, Utah, is a designer, manufacturer and marketer of single‐use medical devices focusing principally on respiratory therapy and patient monitoring applications. Since its founding in the late 1970s, the company has built a reputation for innovation in airway management and non‐invasive monitoring products used in acute and long‐term care settings.

The company’s core product portfolio includes tracheostomy tubes and related accessories, endotracheal tube holders, disposable catheters and sensors for measuring end‐tidal carbon dioxide (CO₂).